Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAMS-AB in Newly Diagnosed Type 1 Diabetes
NCT04114357Phase 1Completed
- Sponsor
- Indiana University
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HAMS-AB in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Indiana University. Primary endpoint: Change in the Gut Microbiome Profile at 4 weeks. Started Jun 2020; status: completed.
02
Drugs
HAMS-AB
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04114357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04114357.